For the year ending 2025-12-31.
| Income Statement | 2025-12-31 | 2024-12-31 | ||
|---|---|---|---|---|
| Depreciation | 0 | 6,693 | ||
| Research and development | 9,428,720 | 10,535,446 | ||
| General and administrative | 6,086,899 | 10,632,028 | ||
| Total operating expenses | 15,515,619 | 21,174,167 | ||
| Operating loss | -15,515,619 | -21,174,167 | ||
| Other income | 26,900 | - | ||
| Other financing costs | 739,935 | - | ||
| Realized and unrealized loss | -299 | -570 | ||
| Interest income | - | 63,574 | ||
| Net loss | -16,228,953 | -21,111,163 | ||
| Deemed dividend related to warrant modification | 0 | 277,119 | ||
| Net loss attributable to common stockholders | -16,228,953 | -21,388,282 | ||
| Basic EPS | -17.4 | -5.34 | ||
| Basic Average Shares | 932,730 | 4,005,994 | ||
Genprex, Inc. (GNPX)
Genprex, Inc. (GNPX)